Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial.

By J. Vaidya, D. Joseph, J. Tobias, M. Bulsara, F. Wenz, C. Saunders, M. Alvarado, H. Flyger, S. Massarut, W. Eiermann and 14 more. The Lancet, 2010

727 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, background): “It is indicated for patients who have unfavourable risk factors for local control such as: age <50 years, grade 3 tumours, extensive DCIS, vascular invasion or non-radical tumour excision (focally— otherwise further surgery should be advocated) [I, A] [70, 71]. accelerated partial breast irradiation”
Upsides and Downsides of Reactive Oxygen Species for Cancer: The Roles of Reactive Oxygen Species in Tumorigenesis, Prevention, and Therapy (2012, neutral): “Other clinical studies for which ROS have been shown to play a role in radiation-induced therapy include patients with prostate cancer (148), NSCLC (104, 107, 144, 290), rectal cancer (81), and breast cancer (309).”
Gold nanoparticles as novel agents for cancer therapy. (2012, background): “therapy, most patients are treated with megavoltage photons produced by a clinical linear accelerator [74, 75].”
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 (2011, result): “Radiation therapy—partial breast irradiation A randomized trial of targeted intraoperative radiotherapy yielded results closely similar to conventional whole-breast irradiation [21].”